---
title: "AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Effects on other drugs"
description: "Formulary evidence on AD109 (aroxybutynin-atomoxetine, Oxnimbi) in Obstructive sleep apnea: Effects on other drugs. Topics: Atomoxetine label: albuterol and other beta2 agonists; Atomoxetine label: antihypertensive drugs and pressor agents; Atomoxetine label: CYP3A and CYP2D6 substrates and cytochrome P450 inhibition; Atomoxetine label: ethanol, methylphenidate, and drugs highly bound to plasma protein; 1 further topic. 5 evidence topics quoted from 2 sources."
canonical: "https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description/effects-on-other-drugs"
published: "2026-11-18T10:43:47-05:00"
modified: "2026-11-18T10:43:47-05:00"
---

# AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Effects on other drugs

<a id="heading-2.1.2.9.2"></a>

## 2.1.2.9.2 Effects of AD109 on Other Drugs

<a id="topic-2.1.2.9.2-1"></a>

### Atomoxetine label: albuterol and other beta2 agonists

> “Increase the frequency of monitoring blood pressure and heart rate and adjust STRATTERA dosage as clinically appropriate.”
> “Systemically administered albuterol (e.g., oral) can be potentiated by atomoxetine, resulting in increases in heart rate and blood pressure.”

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="topic-2.1.2.9.2-2"></a>

### Atomoxetine label: antihypertensive drugs and pressor agents

> “Increase the frequency of monitoring blood pressure and adjust STRATTERA dosage as clinically appropriate.”
> “Because of increased risk of increased blood pressure, STRATTERA should be used cautiously with antihypertensive drugs, other drugs that increase blood pressure or pressor drugs (e.g., dopamine, dobutamine).”

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="topic-2.1.2.9.2-3"></a>

### Atomoxetine label: CYP3A and CYP2D6 substrates and cytochrome P450 inhibition

> “Concomitant use of STRATTERA (60 mg twice daily for 12 days) with midazolam (CYP3A substrate) (single dose of 5 mg), resulted in 15% increase in the midazolam AUC. This pharmacokinetic change is not clinically significant.”
> “Concomitant use of STRATTERA (40 or 60 mg twice daily for 13 days) with desipramine, (CYP2D6 substrate) (single dose of 50 mg), did not alter the desipramine pharmacokinetics.”
> “Atomoxetine did not cause clinically important inhibition or induction of cytochrome P450 enzymes (including CYP1A2, CYP3A, CYP2D6, and CYP2C9).”

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="topic-2.1.2.9.2-4"></a>

### Atomoxetine label: ethanol, methylphenidate, and drugs highly bound to plasma protein

> “Consumption of ethanol with STRATTERA did not change the intoxicating effects of ethanol.”
> “Concomitant use of STRATTERA with methylphenidate did not increase cardiovascular effects beyond those seen with methylphenidate alone.”
> “Atomoxetine did not affect the binding of warfarin, acetylsalicylic acid, phenytoin, or diazepam to human albumin.”

Source: [Lilly STRATTERA prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021411s053lbl.pdf)

<a id="topic-2.1.2.9.2-5"></a>

### Oxybutynin label: absorption of concomitant drugs and prokinetic agents

> “Anticholinergic agents may potentially alter the absorption of some concomitantly administered drugs due to anticholinergic effects on gastrointestinal motility. This may be of concern for drugs with a narrow therapeutic index. Anticholinergic agents may also antagonize the effects of prokinetic agents, such as metoclopramide.”

Source: [Janssen DITROPAN XL prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/020897s038lbl.pdf)

## Related pages
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Terms and abbreviations](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/terms-and-abbreviations.md)
- [AD109 (aroxybutynin-atomoxetine): Obstructive sleep apnea](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/executive-summary.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Product information and disease description](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/product-information-and-disease-description.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Clinical evidence](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/clinical-evidence.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: Economic information and modeling report](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/economics.md)
- [AD109 (aroxybutynin-atomoxetine) in Obstructive sleep apnea: References](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references) · [Markdown](https://www.evicenter.com/drugs/ad109--obstructive-sleep-apnea/references.md)
